688238 和元生物
2026/03 - 三个月2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)-3.841-14.935-16.946-6.0492.541
总资产报酬率 ROA (%)-2.596-10.742-13.167-5.0172.088
投入资产回报率 ROIC (%)-2.861-12.064-14.951-5.5852.302

边际利润分析
销售毛利率 (%)-23.847-14.521-37.808-6.37444.411
营业利润率 (%)-105.342-86.948-125.106-75.90014.318
息税前利润/营业总收入 (%)-107.668-84.755-125.825-83.8864.865
净利润/营业总收入 (%)-104.994-87.715-129.834-62.40813.476

收益指标分析
经营活动净收益/利润总额(%)103.26196.28389.823100.11285.566
价值变动净收益/利润总额(%)0.378-2.650-0.0840.7435.510
营业外收支净额/利润总额(%)0.0000.1380.6960.101-0.201

偿债能力分析
流动比率 (X)1.2831.2322.0932.9527.836
速动比率 (X)1.0741.0771.8692.6957.484
资产负债率 (%)32.06932.68423.86220.93813.009
带息债务/全部投入资本 (%)20.42719.7819.1676.4201.050
股东权益/带息债务 (%)363.277377.804942.8691,398.7449,037.552
股东权益/负债合计 (%)211.567205.956319.115377.573668.693
利息保障倍数 (X)46.267-36.633-793.20410.606-0.516

营运能力分析
应收账款周转天数 (天)168.710115.405106.803129.20465.895
存货周转天数 (天)105.19783.88881.377121.037121.920